Ionis Pharmaceuticals/IONS

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ticker

IONS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Carlsbad, United States

Employees

927
Website
www.ionispharma.com

IONS Metrics

BasicAdvanced
$6.6B
Market cap
-
P/E ratio
-$2.67
EPS
0.41
Beta
-
Dividend rate
$6.6B
0.41
7.373
6.775
649.099
667.434
-4.25%
-8.13%
-98.29%
8.36
22.18
22.18
-18.8
34.75%
15.71%
3.13%
-8.84%

What the Analysts think about IONS

Analyst Ratings

Majority rating from 24 analysts.
Buy

IONS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-119.59% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$119M
-63.20%
Net income
-$143M
1,452.17%
Profit margin
-119.59%
4,125.80%

IONS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.78%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.60
-$1.03
-$0.06
-$0.98
-
Expected
-$0.90
-$1.04
-$0.83
-$1.05
-$0.94
Surprise
-33.46%
-1.05%
-92.78%
-6.78%
-

IONS News

AllArticlesVideos

This cheap biotech offers investors a play on ALS if trial data continues to impress

Market Watch·2 days ago

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed

PRNewsWire·1 week ago

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema

PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals (IONS) has a market cap of $6.6B as of July 04, 2024.

What is the P/E ratio for Ionis Pharmaceuticals stock?

The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of July 04, 2024.

Does Ionis Pharmaceuticals stock pay dividends?

No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Ionis Pharmaceuticals dividend payment date?

Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.

What is the beta indicator for Ionis Pharmaceuticals?

Ionis Pharmaceuticals (IONS) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Ionis Pharmaceuticals stock

Buy or sell Ionis Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing